Shanghai Henlius Biotech, Inc. (Henlius) will convene its 2026 annual general meeting on 19 May 2026 at 3:00 p.m. in Shanghai (10th Floor, B8 Building, 188 Yizhou Road, Xuhui District).
Key ordinary resolutions: • 2025 annual report, Board report, Supervisory Board report and final accounts will be submitted for approval. • A 2025 profit-distribution proposal will be voted on (details not disclosed in the notice). • Ernst & Young Hua Ming LLP (domestic) and Ernst & Young (international) are nominated for re-appointment as 2026 auditors, with 2025 remuneration packages to be confirmed. • Remuneration of the full-time executive director for 2025 will be determined.
Key special resolutions: • Share-issuance mandate: the Board may issue, allot or deal with up to 20% of the Company’s total issued share capital (excluding treasury shares) during the mandate period, which runs until the next AGM or an earlier revocation. The mandate covers shares, convertible bonds, warrants and similar instruments and authorises the Board to set all issuance terms and amend the Articles of Association to reflect any capital increase. • H-share repurchase mandate: the Board may repurchase up to 10% of issued H shares (excluding treasury shares) on the Hong Kong Stock Exchange within the same mandate period. The Board may cancel repurchased shares, hold them as treasury shares, or amend the Articles of Association to reflect any capital reduction.
Administrative notes: • Shareholders recorded on 19 May 2026 are entitled to attend and vote; the register will be closed from 14 May 2026 to 19 May 2026. • Proxy forms must arrive by 3:00 p.m. on 18 May 2026.
The resolutions will be decided by poll in accordance with the Listing Rules.
Comments